A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT ID: NCT07023341
Last Updated: 2026-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
34 participants
INTERVENTIONAL
2025-06-30
2028-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Obstructive hypertrophic cardiomyopathy (oHCM) is a type of heart disease where the heart muscles become thicker than normal due to over contraction. This thickening makes it harder than normal due to over contraction. This thickening makes it harder for the heart to pump blood out to the rest of the body. In symptomatic oHCM people with the condition experience symptoms like shortness of breath, chest pain, fainting, high blood pressure and irregular heartbeats.
The study treatment aficamten, also called BAY3723113, is under development to treat symptomatic oHCM. It aims to reduce the activity of cardiac myosin, a protein that helps heart muscles to contract, and thereby preventing over contraction and muscle thickening.
Although treatment options are available for symptomatic oHCM, there is still need for other treatment options that help target the root cause of the condition. In this study, researchers want to understand about the effects and long-term safety of aficamten in Japanese people with symptomatic oHCM.
The main purpose of the study is to learn how well aficamten works in Japanese with symptomatic oCHM.
For this, the researchers will check how participant's heart blood flow changes after 6 months of treatment. They do this by measuring the pressure needed for blood to leave the heart using a test called the left ventricular outflow tract (LVOT) gradient and a special breathing technique called Valsava maneuver.
Researchers will also look for:
* the number of participants who will have at least 1 level improvement on a scale doctors use to assess the effect of heart problems on daily activities after 3 and 6 months of treatment
* the change in the impact of heart problems on participant's daily lives based on their feedback on a questionnaire called Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) after 3 and 6 months of treatment.
This study will have 2 treatment periods: main treatment period and long-term treatment period. During the main treatment period, participants will take aficamten tablets once daily by mouth for up to 6 months. After completing this period, the participants who can join the long-term treatment period will continue taking aficamten until the drug becomes commercially available in Japan or the study ends.
Each participant will be in the study as long as they benefit from the treatment.
Participants will visit the study site:
* once before the treatment starts
* 9 times with a gap of 2 to 4 weeks between the visits during treatment under the main treatment period, and in the long-term treatment period, participants will visit almost every 3 months until the treatment ends.
* then 2 more times with a gap of 1 month between the visits after the treatment ends.
During the study, the study doctors and their team will:
* check participant's health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG) and echocardiogram (ECHO)
* ask the participants questions about how they are feeling and what adverse events are they having
An adverse event is any medical problem that a participant has during a study. Study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study.
If the participant benefits from the treatment, treatment with aficamten after the end of the study might be possible.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
NCT05414175
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
NCT06081894
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT05767346
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
NCT06116968
Aficamten vs Placebo in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM)
NCT05186818
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aficamten (BAY3723113)
Aficamten will be administered orally once daily with or without food. Participants in this arm will receive a single daily oral dose of 5 mg, 10 mg, 15 mg, or 20 mg of Aficamten with dose levels guided by echocardiography assessments, for up to 24 weeks. Participants will receive a dose of Aficamten until the drug becomes commercially available in Japan or the study ends.
BAY3723113
Oral tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BAY3723113
Oral tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with HCM per the following criteria:
1. Has LV hypertrophy and non-dilated LV chamber in the absence of other cardiac disease and
2. Has an end-diastolic LV wall thickness as measured by the echocardiography core laboratory of:
1. ≥15 mm in one or more myocardial segments OR
2. ≥13 mm in one or more wall segments and a known-disease-causing gene mutation or positive family history of HCM
* Has resting LVOT-G ≥ 30 mmHg and Valsalva LVOT-G =50 mmHg during screening as determined by the echocardiography core laboratory
* LVEF ≥ 60% at screening as determined by the echocardiography core laboratory
* NYHA Functional Class II or III at screening
* Hemoglobin ≥10 g/dL at screening
* Body mass index \<35 kg/m²
* Japanese
* Patients on beta-blockers, verapamil, diltiazem, or disopyramide/cibenzoline should have been on a stable regimen for \>6 weeks prior to the first dose of aficamten and anticipate remaining on the same medication regimen at least during the main study treatment period. Patients treated with disopyramide or cibenzoline must also be concomitantly treated with a beta blocker and/or calcium channel blocker.
Exclusion Criteria
1. Moderate-severe valvular aortic stenosis and/or regurgitation
2. Moderate-severe mitral regurgitation not due to systolic anterior motion of the mitral valve
* Known or suspected infiltrative, genetic or storage disorder causing cardiac hypertrophy that mimics oHCM (e.g., Noonan syndrome, Fabry disease, amyloidosis)
* History of LV systolic dysfunction (LVEF \<45%) or stress cardiomyopathy at any time during their clinical course
* Documented paroxysmal atrial fibrillation during the screening period
* Paroxysmal or persistent/permanent atrial fibrillation is only excluded IF:
* Rhythm restoring treatment (e.g., direct-current cardioversion, atrial fibrillation ablation procedure, or antiarrhythmic therapy) has been required ≤ 6 months prior to screening
* Rate control and anticoagulation have not been achieved for at least 6 months prior to screening
* Has been treated with SRT (surgical myectomy or percutaneous alcohol septal ablation) or cannot postpone plans for SRT until after the study period
* History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to screening
* Has received prior treatment with aficamten or mavacamten
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kurume University Hospital
Kurume, Fukuoka, Japan
Hyogo Prefectural HarimaHimeji General Medical Center
Himeji, Hyōgo, Japan
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
University of Tsukuba Hospital
Tsukuba, Ibaraki, Japan
Iwate Prefectural Central Hospital
Morioka, Iwate, Japan
Kitasato University Hospital
Sagamihara, Kanagawa, Japan
SHOWA Medical University Fujigaoka Hospital
Yokohama, Kanagawa, Japan
Kochi Medical School Hospital
Nankoku, Kochi, Japan
Mie University Hospital
Tsu, Mie-ken, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Saiseikai Kumamoto Hospital
Kumamoto, Mumamoto, Japan
Kurashiki Central Hospital
Kurashiki, Okayama-ken, Japan
University of the Ryukyus Hospital
Ginowan, Okinawa, Japan
Matsushita Memorial Hospital
Moriguchi, Osaka, Japan
National Cerebral and Cardiovascular Center
Suita, Osaka, Japan
The University of Osaka Hospital
Suita, Osaka, Japan
Hamamatsu University Hospital
Hamamatsu, Shizuoka, Japan
Nippon Medical School Hospital
Bunkyo-ku, Tokyo, Japan
The University of Tokyo Hospital
Bunkyo, Tokyo, Japan
Sakakibara Heart Institute
Fuchū, Tokyo, Japan
Showa Medical University Koto Toyosu Hospital
Koto, Tokyo, Japan
Saiseikai Fukuoka General Hospital
Fukuoka, , Japan
Gifu University Hospital
Gifu, , Japan
Kumamoto University Hospital
Kumamoto, , Japan
University Hospital, Kyoto Prefectural University of Medicine
Kyoto, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Click here to find further information and, after study completion, the study results according to Bayer's transparency standards.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22976
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.